Epidemiology of invasive Streptococcus pyogenes disease in Germany during 2003-2007

FEMS Immunology and Medical Microbiology

Volumn 58, Issue 3, 2010, Pages 389-396

  Imöhl, Matthias ^a   Reinert, Ralf René ^a   Ocklenburg, Christina ^a   Van Der Linden, Mark ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Antimicrobial susceptibility; emm type; Epidemiology; Invasive infections; Risk factors; Streptococcus pyogenes

Indexed keywords

CEFOTAXIME; CLARITHROMYCIN; CLINDAMYCIN; LEVOFLOXACIN; PENICILLIN G; TETRACYCLINE;

ADULT; AGED; ALCOHOLISM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL ARTHRITIS; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD; CEREBROSPINAL FLUID; CHICKENPOX; CHILD; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; GENE IDENTIFICATION; GERMANY; GROUP A STREPTOCOCCAL INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION RISK; KIDNEY DISEASE; MALE; NECROTIZING FASCIITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PERITONEAL FLUID; PHLEGMON; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RESPIRATORY DISTRESS; SCHOOL CHILD; SEASONAL VARIATION; SEPSIS; SHOCK; SKIN DEFECT; STREPTOCOCCUS PYOGENES; TISSUE NECROSIS; TOXIC SHOCK SYNDROME;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; FASCIITIS, NECROTIZING; FEMALE; GERMANY; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POPULATION SURVEILLANCE; SEPSIS; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; YOUNG ADULT;

EID: 77949401242     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2010.00652.x     Document Type: Article

References (60)

1. Andersen MM & Ronne T (1995) Group A streptococcal bacteraemias in Denmark 1987-89. J Infection 31: 33-37.
2. Arvand M, Hoeck M, Hahn H & Wagner J (2000) Antimicrobial resistance in Streptococcus pyogenes isolates in Berlin. J Antimicrob Chemoth 46: 621-624.
3. Bassetti M, Manno G, Collida A et al. (2000) Erythromycin resistance in Streptococcus pyogenes in Italy. Emerg Infect Dis 6: 180-183.
4. Bingen E, Bidet P, Mihaila-Amrouche L et al. (2004) Emergence of macrolide-resistant Streptococcus pyogenes strains in French children. Antimicrob Agents Ch 48: 3559-3562.
5. Brandt CM, Schweizer KG, Holland R, L̈utticken R & Freyaldenhoven BS (2005) Lack of mitogenic activity of speG- and speG(dys)-positive Streptococcus dysgalactiae subspecies equisimilis isolates from patients with invasive infections. Int J Med Microbiol 295: 539-546.
6. Carapetis JR, Steer AC, Mulholland EK & Weber M (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5: 685-694.
7. Cleary PP, Kaplan EL, Handley JP, Wlazlo A, Kim MH, Hauser AR & Schlievert PM (1992) Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet 339: 518-521.
8. Clinical Laboratory Standards Institute (2008) Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. Clinical Laboratory Standards Institute, Wayne, PA.
9. Creti R, Imperi M, Baldassarri L, Pataracchia M, Recchia S, Alfarone G & Orefici G (2007) Emm types, virulence factors, and antibiotic resistance of invasive Streptococcus pyogenes isolates from Italy: what has changed in 11 years? J Clin Microbiol 45: 2249-2256.
10. Cunningham MW (2000) Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 13: 470-511.
11. Darenberg J, Luca-Harari B, Jasir A et al. (2007) Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis 45: 450-458.
12. De Azavedo JC, Yeung RH, Bast DJ, Duncan CL, Borgia SB & Low DE (1999) Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob Agents Ch 43: 2144-2147.
13. Demers B, Simor AE, Vellend H et al. (1993) Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 16: 792-800; discussion 801-792.
14. Descheemaeker P, Van Loock F, Hauchecorne M, Vandamme P & Goossens H (2000) Molecular characterisation of group A streptococci from invasive and non-invasive disease episodes in Belgium during 1993-1994. J Med Microbiol 49: 467-471.
15. Efstratiou A, Emery M, Lamagni TL, Tanna A, Warner M & George RC (2003) Increasing incidence of group A streptococcal infections amongst injecting drug users in England and Wales. J Med Microbiol 52: 525-526.
16. Ekelund K, Skinhoj P, Madsen J & Konradsen HB (2005) Reemergence of emm1 and a changed superantigen profile for group A streptococci causing invasive infections: results from a nationwide study. J Clin Microbiol 43: 1789-1796.
17. Eriksson BK, Andersson J, Holm SE & NorgrenM(1999) Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Infect Dis 180: 410-418.
18. Fraser JD & Proft T (2008) The bacterial superantigen and superantigen-like proteins. Immunol Rev 225: 226-243.
19. Gene A, Ardanuy C, Palacin E & Garcia-Garcia JJ (2006) Increasing methylase-mediated resistance to macrolides in Streptococcus pyogenes in a children's hospital in Barcelona (Spain). Enferm Infec Micr Cl 24: 26-28.
20. Giovanetti E, Montanari MP, Mingoia M & Varaldo PE (1999) Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains. Antimicrob Agents Ch 43: 1935-1940.
21. Granizo JJ, Aguilar L, Casal J, Dal-Re R & Baquero F (2000) Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). J Antimicrob Chemoth 46: 959-964.
22. Haukness HA, Tanz RR, Thomson RB Jr et al. (2002) The heterogeneity of endemic community pediatric group A streptococcal pharyngeal isolates and their relationship to invasive isolates. J Infect Dis 185: 915-920.
23. Holm SE, Norrby A, Bergholm AM & Norgren M (1992) Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 166: 31-37.
24. Ikebe T, Hirasawa K, Suzuki R et al. (2005) Antimicrobial susceptibility survey of Streptococcus pyogenes isolated in Japan from patients with severe invasive group A streptococcal infections. Antimicrob Agents Ch 49: 788-790.
25. Ikebe T, Hirasawa K, Suzuki R et al. (2007) Distribution of emm genotypes among group A Streptococcus isolates from patients with severe invasive streptococcal infections in Japan, 2001-2005. Epidemiol Infect 135: 1227-1229.
26. Katz AR & Morens DM (1992) Severe streptococcal infections in historical perspective. Clin Infect Dis 14: 298-307.
27. Katz KC, McGeer AJ, Duncan CL et al. (2003) Emergence of macrolide resistance in throat culture isolates of group A streptococci in Ontario, Canada, in 2001. Antimicrob Agents Ch 47: 2370-2372.
28. Kiska DL, Thiede B, Caracciolo J et al. (1997) Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J Infect Dis 176: 992-1000.
29. Lamagni TL, Efstratiou A, Vuopio-Varkila J, Jasir A & Schalen C (2005) The epidemiology of severe Streptococcus pyogenes associated disease in Europe. Euro Surveill 10: 179-184.
30. Lamagni TL, Neal S, Keshishian C et al. (2008a) Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004. Emerg Infect Dis 14: 202-209.
31. Lamagni TL, Darenberg J, Luca-Harari B et al. (2008b) Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 46: 2359-2367.
32. Lloyd CA, Jacob SE & Menon T (2007) Antibiotic resistant betahemolytic streptococci. Indian J Pediatr 74: 1077-1080.
33. Luca-Harari B, Ekelund K, van der Linden M, Staum-Kaltoft M, Hammerum AM & Jasir A (2008) Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004. J Clin Microbiol 46: 79-86.
34. Martin PR & Hoiby EA (1990) Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis 22: 421-429.
35. Musser JM, Hauser AR, Kim MH, Schlievert PM, Nelson K & Selander RK (1991) Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. P Natl Acad Sci USA 88: 2668-2672.
36. Nakae M, Murai T, Kaneko Y & Mitsuhashi S (1977) Drug resistance in Streptococcus pyogenes isolated in Japan. Antimicrob Agents Ch 12: 427-428.
37. Norton R, Smith HV,Wood N, Siegbrecht E, Ross A & Ketheesan N (2004) Invasive group A streptococcal disease in North Queensland (1996-2001). Indian J Med Res 119 (suppl): 148-151.
38. O'Brien KL, Beall B, Barrett NL et al. (2002) Epidemiology of invasive group A Streptococcus disease in the United States, 1995-1999. Clin Infect Dis 35: 268-276.
39. O'Grady KA, Kelpie L, Andrews RM et al. (2007) The epidemiology of invasive group A streptococcal disease in Victoria, Australia. Med J Australia 186: 565-569.
40. O'Loughlin RE, Roberson A, Cieslak PR et al. (2007) The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 45: 853-862.
41. Perez-Trallero E, Urbieta M, Montes M, Ayestaran I & Marimon JM (1998) Emergence of Streptococcus pyogenes strains resistant to erythromycin in Gipuzkoa, Spain. Eur J Clin Microbiol 17: 25-31.
42. Perez-Trallero E, Montes M, Orden B, Tamayo E, Garcia-Arenzana JM & Marimon JM (2007) Phenotypic and genotypic characterization of Streptococcus pyogenes isolates displaying the MLSB phenotype of macrolide resistance in Spain, 1999 to 2005. Antimicrob Agents Ch 51: 1228-1233.
43. Podbielski A, Melzer B & Lütticken R (1991) Application of the polymerase chain reaction to study the M protein(-like) gene family in beta-hemolytic streptococci. Med Microbiol Immun 180: 213-227.
44. Richter SS, Heilmann KP, Dohrn CL et al. (2008) Increasing telithromycin resistance among Streptococcus pyogenes in Europe. J Antimicrob Chemoth 61: 603-611.
45. Rivera A, Rebollo M, Miro E et al. (2006) Superantigen gene profile, emm type and antibiotic resistance genes among group A streptococcal isolates from Barcelona, Spain. J Med Microbiol 55: 1115-1123.
46. Rogers S, Commons R, Danchin MH et al. (2007) Strain prevalence, rather than innate virulence potential, is the major factor responsible for an increase in serious group A Streptococcus infections. J Infect Dis 195: 1625-1633.
47. Schmitz FJ, Beyer A, Charpentier E et al. (2003) Toxin-gene profile heterogeneity among endemic invasive European group A streptococcal isolates. J Infect Dis 188: 1578-1586.
48. Siljander T, Toropainen M, Muotiala A, Hoe NP, Musser JM & Vuopio-Varkila J (2006) emm typing of invasive T28 group A streptococci, 1995-2004, Finland. J Med Microbiol 55: 1701-1706.
49. Stevens DL, Tanner MH,Winship J, Swarts R, Ries KM, Schlievert PM & Kaplan E (1989) Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. New Engl J Med 321: 1-7.
50. Stromberg A, Romanus V & Burman LG (1991) Outbreak of group A streptococcal bacteremia in Sweden: an epidemiologic and clinical study. J Infect Dis 164: 595-598.
51. Szczypa K, Sadowy E, Izdebski R, Strakova L & Hryniewicz W (2006) Group A streptococci from invasive-disease episodes in Poland are remarkably divergent at the molecular level. J Clin Microbiol 44: 3975-3979.
52. Talkington DF, Schwartz B, Black CM, Todd JK, Elliott J, Breiman RF & Facklam RR (1993) Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun 61: 3369-3374.
53. Tamayo J, Perez-Trallero E, Gomez-Garces JL & Alos JI (2005) Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004. J Antimicrob Chemoth 56: 780-782.
54. The Working Group on Severe Streptococcal Infections (1993) Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. J Am Med Assoc 269: 390-391.
55. Uh Y, Jang IH, Hwang GY, Lee MK, Yoon KJ & Kim HY (2004) Antimicrobial susceptibility patterns and macrolide resistance genes of beta-hemolytic streptococci in Korea. Antimicrob Agents Ch 48: 2716-2718.
56. Veasy LG, Wiedmeier SE, Orsmond GS et al. (1987) Resurgence of acute rheumatic fever in the intermountain area of the United States. New Engl J Med 316: 421-427.
57. Vlaminckx BJ, Mascini EM, Schellekens J et al. (2003) Sitespecific manifestations of invasive group A streptococcal disease: type distribution and corresponding patterns of virulence determinants. J Clin Microbiol 41: 4941-4949.
58. Vlaminckx BJ, van Pelt W, Schouls LM et al. (2005) Long-term surveillance of invasive group A streptococcal disease in the Netherlands, 1994-2003. Clin Microbiol Infec 11: 226-231.
59. Wahl RU, Lütticken R, Stanzel S, van der Linden M & Reinert RR (2007) Epidemiology of invasive Streptococcus pyogenes infections in Germany, 1996-2002: results from a voluntary laboratory surveillance system. Clin Microbiol Infec 13: 1173-1178.
60. Weber P, Filipecki J, Bingen E et al. (2001) Genetic and phenotypic characterization of macrolide resistance in group A streptococci isolated from adults with pharyngo-tonsillitis in France. J Antimicrob Chemoth 48: 291-294.